Home » Stocks » Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Stock Price: $6.79 USD 0.52 (8.29%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 492.21M
Revenue (ttm) 36.02M
Net Income (ttm) -74.88M
Shares Out 72.49M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $6.79
Previous Close $6.27
Change ($) 0.52
Change (%) 8.29%
Day's Open 6.42
Day's Range 6.40 - 6.94
Day's Volume 1,678,201
52-Week Range 3.29 - 8.78

More Stats

Market Cap 492.21M
Enterprise Value 454.63M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 72.49M
Float 63.84M
EPS (basic) -1.13
EPS (diluted) -1.14
FCF / Share -1.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 13.36M
Short Ratio 8.11
Short % of Float 24.51%
Beta 1.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.66
PB Ratio 20.03
Revenue 36.02M
Operating Income -80.47M
Net Income -74.88M
Free Cash Flow -86.77M
Net Cash 37.58M
Net Cash / Share 0.52
Gross Margin -148.42%
Operating Margin -223.40%
Profit Margin -207.90%
FCF Margin -240.90%
ROA -60.38%
ROE -230.41%
ROIC 861.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(280.85% upside)
Current: $6.79
Target: 25.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth649.51%97.62%27.66%194.8%---
Gross Profit36.144.822.441.910.65--
Operating Income-77.10-56.75-32.56-19.99-8.85-2.65-0.56
Net Income-71.45-55.67-32.42-20.00-8.85-2.54-0.60
Shares Outstanding63.9057.0050.1841.1431.3520.166.96
Earnings Per Share-1.12-0.98-0.65-0.49-0.28-0.13-0.09
Operating Cash Flow-45.72-30.07-27.80-13.57-4.62-2.36-0.37
Capital Expenditures-2.74-2.30-0.71-0.35-0.11-0.06-
Free Cash Flow-48.46-32.37-28.50-13.92-4.74-2.43-0.37
Cash & Equivalents31.7541.7562.7015.1912.376.280.30
Total Debt9.450.390.330.
Net Cash / Debt22.3041.3562.3614.9212.216.13-0.34
Book Value6.1627.5257.788.928.995.86-1.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Corbus Pharmaceuticals Holdings, Inc.
Country United States
Employees 141
CEO Yuval Cohen

Stock Information

Ticker Symbol CRBP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRBP


Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.